Gilead upgraded to Outperform from Neutral at Credit Suisse Credit Suisse upgraded Gilead due to its Sofosbuvir franchise opportunity. Price target raised to $55 from $40.
News For GILD From The Last 14 Days
Check below for free stories on GILD the last two weeks.